证券代码：300158 证券简称：振东制药 公告编号：2025-016 山西振东制药股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西振东制药股份有限公司（以下简称"公司"）第六届董事会第 三次会议于 2025 年 4 月 18 日上午 9:00 在公司会议室通过现场及通 讯表决方式召开，会议通知于 2025 年 4 月 8 日以电话、邮件等方式 通知全体董事。会议应出席董事 9 名，实际出席董事 9 名。会议由李 昆先生主持，公司监事及高级管理人员列席会议。本次会议的出席人 数、召集、召开程序和议事内容均符合国家有关法律法规及《公司章 程》的规定。 二、董事会会议审议情况 《2024 年年度财务报告》内容详见中国证监会创业板指定信息 披露网站。 本议案已由董事会审计委员会审议通过。 1、会议以9票同意、0票反对、0票弃权，审议通过了《2024年度 董事会工作报告》。 《2024 年度董事会工作报告》内容详见中国证监会创业板指定 信息披露网站。 公司独立董事吕万良、靳黎娜、秦雪梅已向董事会 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-018 山西振东制药股份有限公司 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"振东制药"、"公司"或"本 公司"）于 2025 年 4 月 18 日召开第六届董事会第三次会议及第六届 监事会第三次会议，审议通过了《2024 年度利润分配预案》，该预 案尚需提交公司股东大会审议。现将预案基本情况公告如下： 一、利润分配预案的基本情况 定 2024 年度不派发现金，不送红股，不以资本公积金转增股本。待 公司符合利润分配相关条件后，公司将严格按照相关法律法规和《公 司章程》等规定，综合考虑与利润分配相关的各种因素，从有利于公 司发展和投资者回报的角度出发进行利润分配。 三、董事会意见 董事会审议并通过了关于公司 2024 年度利润分配预案的议案， 同意将 2024 年度利润分配预案提交股东大会审议。 四、监事会意见 监事会认为：公司董事会提出的 2024 年度利润分配预案符合相 关法律、法规以及《公司章程》的规定，符合公司 ...

Financial Performance - In 2024, Shanxi Zhendong Pharmaceutical achieved operating revenue of CNY 2.971 billion, a year-on-year decrease attributed to external factors such as price drops from centralized procurement and reduced foot traffic in retail due to policy changes [6]. - The net profit attributable to shareholders for 2024 was CNY -1.329 billion, significantly impacted by non-operating factors including major arbitration issues and inventory impairment [6]. - The company's operating revenue for 2024 was ¥2,971,127,572.67, a decrease of 18.06% compared to ¥3,626,016,132.88 in 2023 [25]. - The net profit attributable to shareholders for 2024 was -¥1,328,563,928.26, representing a significant decline of 2,920.55% from -¥43,984,116.23 in 2023 [25]. - The net cash flow from operating activities for 2024 was -¥149,822,253.09, an improvement of 39.87% compared to -¥249,172,200.21 in 2023 [25]. - The total assets at the end of 2024 were ¥4,982,724,545.73, down 19.38% from ¥6,180,497,035.31 at the end of 2023 [25]. - The net assets attributable to shareholders decreased by 28.60% to ¥3,697,629,286.45 at the end of 2024 from ¥5,178,856,723.52 at the end of 2023 [25]. - The company reported a basic earnings per share of -¥1.2977 for 2024, a decline of 2,932.01% from -¥0.0428 in 2023 [25]. - The company experienced a significant increase in non-recurring losses, with total non-recurring losses amounting to -¥642,224,001.50 in 2024 compared to a profit of ¥72,080,014.16 in 2023 [33]. - The company reported a quarterly revenue of ¥701,702,757.52 in Q4 2024, with a significant net loss of -¥1,368,687,231.38 for the same quarter [28]. Market Trends and Industry Outlook - The pharmaceutical industry is expected to continue its long-term positive trend due to increasing health demands and an aging population, indicating potential future growth opportunities for the company [36]. - The overall price index in the traditional Chinese medicine sector declined by 9.6% year-on-year, indicating a downturn in market activity and increased inventory pressure [6]. - The retail pharmacy industry experienced a closure rate increase to 5.7%, reflecting the adverse effects of outpatient policy implementation and personal account reforms in medical insurance [6]. - The domestic hair loss treatment market is estimated to reach RMB 138.1 billion by 2030, with the current market size around RMB 11.4 billion and an average growth rate of 15% in recent years [39]. - The market size of the Chinese medicine industry exceeded RMB 400 billion in 2023, with a compound annual growth rate of 2.13% from 2015 to 2023 [40]. - The number of innovative Chinese medicine applications increased by 37% in 2023, with 41 clinical approvals, marking a 64% year-on-year growth [40]. Product Development and R&D - The company has developed a comprehensive R&D system with three specialized centers focusing on innovative drug discovery, generic drugs, and complex formulations [53]. - The company invested CNY 251 million in R&D during the reporting period, representing a year-on-year increase of 25.27% [82]. - The company has over 130 ongoing R&D projects and has undertaken more than 50 national and provincial-level projects [72]. - The company has several products in the clinical approval stage, including Minocycline foam (1.5% and 4%) for acne, and Minoxidil foam for hair loss, all currently in clinical trials [65]. - The company plans to enrich its oncology product pipeline with new products such as Cabozantinib and ZD-09, which are currently in various stages of development [107]. - The company has received production approvals for multiple new products, including Minoxidil and various oncology drugs, which will enrich the product line [108]. Strategic Initiatives and Marketing - The company employs a specialized marketing model, covering 81% of prefecture-level cities and 87% of county-level cities in China, with over 20,000 medical terminals [47]. - The OTC sales model combines self-operated sales with distribution partnerships, enhancing market penetration, especially in remote areas [48]. - The company is actively pursuing strategic marketing networks through national industry platforms and regional招商会 to enhance market penetration [51]. - The company’s online sales strategy includes traditional e-commerce, interest e-commerce, and private domain e-commerce, aiming to enhance brand influence and market competitiveness [50]. - The company aims to position itself as an "innovation-driven marketing" enterprise, focusing on areas such as dermatological drugs and traditional Chinese medicine [132]. Governance and Management - The company has a performance evaluation and incentive mechanism linking the performance of directors and senior management to their compensation [156]. - The company has established various committees under the board to provide professional opinions for decision-making [154]. - The company is actively managing its governance structure in response to recent changes in leadership and board composition [165]. - The company announced the resignation of Chairman Li Anping on April 19, 2024, due to personal reasons, and he will no longer hold any position in the company [163]. - The company is committed to enhancing its corporate governance and compliance following recent regulatory scrutiny [180]. Employee and Workforce Management - The total number of employees at the end of the reporting period is 3,720, with 1,740 in sales, 1,002 in production, and 476 in technical roles [193]. - The company has a structured training program with a minimum of 120 hours of training per employee annually, aiming to enhance professional skills and management capabilities [196]. - The employee stock ownership plan includes 1,223 employees holding a total of 38,967,619 shares, representing 3.88% of the company's total equity [200]. - The company is committed to enhancing employee satisfaction and engagement through various incentive measures and a transparent compensation structure [194]. Financial Governance and Compliance - The company received a warning letter from the China Securities Regulatory Commission on March 6, 2023, regarding administrative measures taken against the company and certain executives [179]. - The company faced disciplinary actions from the Shenzhen Stock Exchange due to fund occupation issues by its controlling shareholder from February 2018 to August 2021, resulting in public reprimands for the company and its executives [180]. - The company continues to ensure compliance with relevant regulations and governance standards in its operations [188].

Financial Performance - The company's revenue for Q1 2025 was ¥754,532,591.77, a decrease of 3.53% compared to ¥782,130,269.05 in the same period last year[4] - Net profit attributable to shareholders was ¥1,157,176.86, down 94.99% from ¥23,101,557.95 year-on-year[4] - Total revenue for the current period was ¥754,532,591.77, a decrease of 3.6% from ¥782,130,269.05 in the previous period[22] - Operating profit for the current period was ¥12,495,546.65, down 61.3% from ¥32,289,666.48 in the previous period[22] - Net profit for the current period is ¥1,005,768.43, down from ¥22,347,124.36 in the previous period, representing a decrease of about 95.5%[23] - Basic and diluted earnings per share decreased from 0.0225 to 0.0012, a drop of approximately 94.7%[23] Cash Flow - The net cash flow from operating activities was -¥330,009,937.17, a significant decline of 1,282.28% compared to -¥23,874,405.33 in the previous year[11] - Operating cash flow for the current period is -330,009,937.17, compared to -23,874,405.33 in the previous period, reflecting a worsening cash flow situation[25] - Investment cash flow for the current period is ¥259,074,434.79, a significant improvement from -¥43,843,437.71 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,634,578,812.78, a decrease of 6.99% from ¥4,982,724,545.73 at the end of the previous year[4] - Total current assets decreased to ¥2,858,122,396.26 from ¥3,215,616,760.00, a reduction of 11.2%[20] - Total liabilities decreased to ¥1,010,858,921.83 from ¥1,322,468,279.14, a decline of 23.5%[21] - The company reported a net loss in retained earnings of ¥1,386,996,474.81, slightly improved from a loss of ¥1,388,153,651.67 in the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 48,584[13] - The company has a total of 302,230,191 CNY ordinary shares held by Shanxi Zhendong Health Industry Group Co., Ltd., which is the controlling shareholder[14] - The third phase employee stock ownership plan holds 38,967,619 CNY ordinary shares, representing a significant portion of the company's equity structure[14] - The company has a total of 6,000,000 CNY ordinary shares held by Hu Wenqin, representing 0.60% of the total shares[14] - Liu Zhenwei holds 5,698,100 CNY ordinary shares, accounting for 0.57% of the total shares[14] - The company has a total of 10,054,000 CNY shares held in a repurchase special securities account, representing 1.00% of the total shares[14] - The company has a total of 41,207,635 CNY shares held by the asset management plan supporting the development of private enterprises[14] - The company has a total of 5,644,300 CNY shares held by Liu Yubin, representing 0.56% of the total shares[14] - The company has a total of 2,728,900 CNY shares held by Zhou Jie, accounting for 0.27% of the total shares[14] Operating Costs and Expenses - Total operating costs decreased to ¥759,035,483.80 from ¥795,147,632.83, reflecting a reduction of 4.5%[22] - The company incurred operating expenses of ¥932,894,187.96, which is an increase compared to ¥841,787,893.34 in the previous period[25] - Research and development expenses increased to ¥48,435,492.50 from ¥38,447,733.67, reflecting a growth of 26.0%[22] Other Financial Metrics - The company reported a basic earnings per share of ¥0.0012, down 94.67% from ¥0.0225 in the same period last year[4] - Investment income for Q1 2025 was ¥3,416,186.80, a decrease of 79.77% compared to the previous year[10] - The company reported a decrease in sales revenue from ¥800,525,339.92 to ¥597,926,743.45, a decline of about 25.3%[25] - Other comprehensive income attributable to the parent company is 652.32, a recovery from -4.44 in the previous period[23] Audit Information - The company has not undergone an audit for the first quarter report[27]

证券代码：300158 证券简称：振东制药 公告编号：2025-012 山西振东制药股份有限公司 关于股东股份解押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 截至公告披露日，上述股东及其一致行动人所持质押股份情况 如下： | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 累计质押 | 占其 | 占公 | 情况 | | 情况 | | | 股东 | 持股数量 | 持股 | 数量 | 所持 | 司总 | 已质押 | 占已质 | 未质押股 | 占未质 | | 名称 | （股） | 比例 | （股） | 股份 | 股本 | 股份限 | 押股份 | 份限售和 | 押股份 | | | | | | 比例 | 比例 | 售和冻 结数量 | 比例 | 冻结数量 | 比例 | | 振东 集团 | 302,230,191 | 30.06% | 204,854,495 | 67.78% | 20.38% | 0 | 0 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-011 山西振东制药股份有限公司 关于回购公司股份比例达 1%暨回购进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cninfo.com.cn）的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律 监 ...

山西振东制药股份有限公司 关于股东股份解押的公告 证券代码：300158 证券简称：振东制药 公告编号：2025-010 截至公告披露日，上述股东及其一致行动人所持质押股份情况 注：上表中出现合计数与各分项数值总和不符，为四舍五入所致。 3、振东集团目前质押的股份不存在平仓风险，不会对公司日 常生产经营等产生重大影响。若后续出现上述风险，振东集团将采 取补充质押、提前购回等方式，避免触及平仓线而引发平仓风险， 并及时通知公司。公司将持续关注其质押情况及质押风险情况，并 按照有关规定及时履行信息披露义务。敬请投资者注意投资风险。 二、备查文件 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 近日接到控股股东山西振东健康产业集团有限公司（以下简称"振 东集团"）通知，获悉其所持有的本公司部分股份解除质押，具体 事项如下： 一、股东股份解押的基本情况 1、本次解除质押基本情况 | 股东 名称 | 是否为控 股股东 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cninfo.com.cn）的相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等相关规定，公司应当在回购期间每个月的前三个交易日内披露 截至上月末的回购进展情况。现将截至上月末的回购进展情况公告如 下： 一、股份回购 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-008 山西振东制药股份有限公司 通知书编号：2025LP00370 申请人：山西振东制药股份有限公司 目前所处审批阶段：IND 获批（临床试验获批） 后续所需的审批流程：NDA 申报、批准 关于中药1.1类新药星蒌承气颗粒获得临床试验批准通知书 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"振东制药"或"公司"）研 发的星蒌承气颗粒近日获得国家药品监督管理局出具的《药物临床试 验批准通知书》，现将相关情况公告如下： 一、药物基本情况 药品名称：星蒌承气颗粒 注册分类：中药 1.1 类 五、备查文件 1、国家药品监督管理局出具的《药物临床试验批准通知书》。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，星蒌承气颗粒临床试验申请符合药品注册的有关要求，在进一 步完善临床试验方案的基础上，同意开展用于急性缺血性脑卒中的临 床试验。 功能主治：化痰清热，通腑泻下。用于缺血性脑卒中急性期痰热 腑实证，症见半身不遂、偏身麻木、言语不利、头晕目眩 ...

一、本次变更签字项目合伙人的情况 证券代码：300158 证券简称：振东制药 公告编号：2025-007 山西振东制药股份有限公司 关于变更签字项目合伙人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 2024 年 4 月 19 日召开公司第五届董事会第十六次会议，审议通过了 《关于续聘 2024 年度审计机构的议案》，同意续聘中审华会计师事 务所（特殊普通合伙）为公司 2024 年度财务审计机构，并于 2024 年 5 月 17 日召开 2023 年度股东大会，审议并通过上述议案。具体内容 详见公司在巨潮资讯网(http://www.cninfo.com.cn)上披露的相关公告。 近日，公司收到中审华会计师事务所（特殊普通合伙）发来的《关 于变更山西振东制药股份有限公司签字项目合伙人的说明函》，现将 具体情况公告如下： 中审华会计师事务所（特殊普通合伙）作为公司 2024 年度财务 报告审计机构，原指派尹丽洁女士作为签字项目合伙人，现因内部工 作调整，指派杨敏兰先生作为签字项目合伙人接替尹丽 ...